Physician profile
Derek Kendall Johnson
NPI 1285622183
$185,097.74
in general payments reported to CMS, 2019-2025
37 companies · $25K in 2025
The $25K reported for 2025 was more than what 93% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $23K · 2021: $17K · 2022: $32K · 2023: $26K · 2024: $33K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $9,412 · Travel and Lodging: $8,779 · Consulting Fee: $2,535 · Honoraria: $1,044 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,630.00 |
| Food and Beverage | $9,411.63 |
| Travel and Lodging | $8,779.09 |
| Consulting Fee | $2,535.00 |
| Honoraria | $1,044.00 |
| Education | $105.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $81,988.81 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Optinose US, INC. | $65,490.66 | 2019-2025 | |
| Glaxosmithkline, LLC. | $17,107.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech, INC. | $4,727.70 | 2020 | |
| Genzyme Corporation | $3,855.12 | 2019-2025 | |
| Genentech USA, INC. | $2,936.53 | 2019-2024 | Xolair |
| Blueprint Medicines Corporation | $1,622.73 | 2022-2025 | Ayvakit |
| Pfizer INC. | $1,397.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,144.54 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $744.57 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Csl Behring | $572.27 | 2020-2025 | Hizentra |
| Kaleo, INC. | $499.68 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $472.62 | 2019-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $353.80 | 2019-2025 | |
| Abbvie INC. | $314.83 | 2022-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.